Agios to Webcast Conference Call of Second Quarter 2022 Financial Results on August 4, 2022
Agios Pharmaceuticals (NASDAQ: AGIO) announced a conference call scheduled for August 4, 2022, at 8:00 a.m. ET, to discuss its Q2 2022 financial results and business updates. Investors can access the live webcast on the company's website, with an archived version available post-event. Agios focuses on therapies for genetically defined diseases and markets a first-in-class pyruvate kinase activator for PK deficiency. The company is also advancing multiple investigational medicines targeting various disorders including sickle cell disease and MDS-associated anemia.
- Strong focus on genetically defined diseases with a diverse clinical pipeline.
- Successful marketing of a first-in-class therapy for PK deficiency.
- None.
CAMBRIDGE, Mass., July 14, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for genetically defined diseases, today announced the company will host a conference call and live webcast on Thursday, August 4, 2022, at 8:00 a.m. ET to report its second quarter 2022 financial results and other business highlights.
A live webcast can be accessed under "Events & Presentations" in the Investors section of the company's website at www.agios.com. The webcast will be archived and made available for replay on the company's website beginning approximately two hours after the event.
About Agios
Agios is a biopharmaceutical company that is fueled by connections. The Agios team cultivates strong bonds with patient communities, healthcare professionals, partners and colleagues to discover, develop and deliver therapies for genetically defined diseases. In the U.S., Agios markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for this rare, lifelong, debilitating hemolytic anemia. Building on the company's leadership in the field of cellular metabolism, Agios is advancing a robust clinical pipeline of investigational medicines with active and planned programs in alpha- and beta-thalassemia, sickle cell disease, pediatric PK deficiency and MDS-associated anemia. In addition to its clinical pipeline, Agios has multiple investigational therapies in preclinical development and an industry-leading research team with unmatched expertise in cellular metabolism and genetics. For more information, please visit the company’s website at www.agios.com.
Contacts
Investors:
Holly Manning, 617-844-6630
Senior Director, Investor Relations
Holly.Manning@agios.com
Media:
Jessica Rennekamp, 857-209-3286
Director, Corporate Communications
Jessica.Rennekamp@agios.com
FAQ
When will Agios Pharmaceuticals report their Q2 2022 financial results?
How can I listen to the Agios Pharmaceuticals conference call?
What is the focus of Agios Pharmaceuticals?
What is the ticker symbol for Agios Pharmaceuticals?
